# Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme

> **NCT00083447** · PHASE3 · WITHDRAWN · sponsor: **Xenova Biomedix** · enrollment: 323 (—)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** TransMID™

## Key facts

- **NCT ID:** NCT00083447
- **Lead sponsor:** Xenova Biomedix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-05
- **Primary completion:** 2006-03
- **Final completion:** 2007-06
- **Target enrollment:** 323 (—)
- **Why stopped:** This study has been withdrawn because the drug would not meet trial criteria for efficacy
- **Last updated:** 2009-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083447, "Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00083447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*